Verily raised $300 million to advance its AI and precision health initiatives while transitioning from an Alphabet subsidiary to an independent company, with Alphabet retaining a significant minority stake. The investment will support Verily's expansion of AI models, commercial opportunities, and collaborations with partners like UCHealth, University of Colorado Anschutz, Samsung, Salesforce, and Nvidia.
Verily's recent $300 million investment round, led by Series X Capital, signals a strong growth trajectory in AI and precision health, specifically through its Verily Pre platform and AI health solutions. The transition to an independent company from under Alphabet's umbrella allows Verily to expand its strategic partnerships, such as those with UCHealth, Samsung, and Nvidia, which are crucial for scaling their AI models and advancing precision medicine. This presents a significant investment opportunity and highlights the critical importance of strategic partnerships in scaling health AI technologies.